Drug Trial Radar · NCT07196657
The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia
Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,116
Planned (sponsor's estimate)
Start
Sep 30, 2025
Primary completion
Jun 30, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Beijing Tiantan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- China-Japan Friendship Hospital; The First Affiliated Hospital of Nanchang University; Peking University Third Hospital; The Fourth Affiliated Hospital of Harbin Medical University; Zhongnan Hospital; Xiangya Hospital of Central South University; The Affiliated Hospital of Yanbian University; The Second Hospital University of South China; LanZhou University
- First posted
- Sep 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. crisugabalin, a new highly selective α2δ ligand, has shown potential in animal models or preliminary clinical trials, but there is insufficient evidence for its application in FM. This study aims to explore the effectiveness and safety of pregabalin or crisugabalin in treating FM, with the aim of providing a better treatment option for FM patients.
Conditions
- Fibromyalgia
- Pregabalin
- Pain
Interventions
PregabalinDrug
For the pregabalin group, treatment will be initiated at a dosage of 150 mg daily, administered into 2 or 3 divided doses. After 3 to 7 days, the dose will be titrated to 300 mg per day, with subsequent incremental increases of 150 mg daily permitted at 3-day to 7-day intervals based on therapeutic response and tolerability, up to a maximum dose of 450 mg daily.
CrisugabalinDrug
For the crisugabalin group, therapy will begin at 20 mg twice daily, with a maximum allowable dose of 40 mg twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of patients achieving pain reliefTime frame: At the 12-weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Beijing, Beijing 100070
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.